← All trials
NCT07282821
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2026
- Primary completion
- Feb 28, 2029
- Completion date
- Aug 1, 2029
- First posted
- Dec 15, 2025
- Last posted
- Dec 17, 2025
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of VermontLead sponsor
- Biomedical Research Institute of New MexicoCollaborator
- Tufts UniversityCollaborator
- Tufts UniversityOfficial
- University of MarylandOfficial
- University of MarylandCollaborator
- University of PittsburghCollaborator
- University of Southern CaliforniaCollaborator
- University of VermontOfficial
- University of VermontSponsor investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.